496 related articles for article (PubMed ID: 35929637)
41. Diagnostic Work-Up of Cardiac Amyloidosis Using Cardiovascular Imaging: Current Standards and Practical Algorithms.
Korosoglou G; Giusca S; André F; Aus dem Siepen F; Nunninger P; Kristen AV; Frey N
Vasc Health Risk Manag; 2021; 17():661-673. PubMed ID: 34720583
[TBL] [Abstract][Full Text] [Related]
42. Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis.
Connors LH; Prokaeva T; Lim A; Théberge R; Falk RH; Doros G; Berg A; Costello CE; O'Hara C; Seldin DC; Skinner M
Am Heart J; 2009 Oct; 158(4):607-14. PubMed ID: 19781421
[TBL] [Abstract][Full Text] [Related]
43. Early Detection of Cardiac Amyloidosis in Transthyretin Mutation Carriers.
Nagano N; Muranaka A; Nishikawa R; Ohwada W; Kouzu H; Kamiyama N; Fujito T; Mochizuki A; Nagahara D; Nakanishi M; Ohkubo Y; Hisahara S; Nakao S; Katoh N; Ishikawa A; Sakurai A; Yano T
Int Heart J; 2022; 63(1):168-175. PubMed ID: 35095067
[TBL] [Abstract][Full Text] [Related]
44. Cardiac amyloidosis: updates in diagnosis and management.
Mohty D; Damy T; Cosnay P; Echahidi N; Casset-Senon D; Virot P; Jaccard A
Arch Cardiovasc Dis; 2013 Oct; 106(10):528-40. PubMed ID: 24070600
[TBL] [Abstract][Full Text] [Related]
45. Amyloidosis in Heart Failure.
Ihne S; Morbach C; Obici L; Palladini G; Störk S
Curr Heart Fail Rep; 2019 Dec; 16(6):285-303. PubMed ID: 31782077
[TBL] [Abstract][Full Text] [Related]
46. Transthyretin cardiac amyloidosis: A treatable form of heart failure with a preserved ejection fraction.
Griffin JM; Maurer MS
Trends Cardiovasc Med; 2021 Jan; 31(1):59-66. PubMed ID: 31889610
[TBL] [Abstract][Full Text] [Related]
47. Multimodality imaging for diagnosis of subclinical hereditary transthyretin cardiac amyloidosis.
Asif T; Vij A; Radzik B; Stern H; Simples P; Ghadiali Q; Malhotra S
J Nucl Cardiol; 2023 Apr; 30(2):792-799. PubMed ID: 34873643
[TBL] [Abstract][Full Text] [Related]
48. Wild-type TTR amyloidosis among patients with unexplained heart failure and systolic LV dysfunction.
Goland S; Volodarsky I; Fabricant Y; Livschitz S; Tshori S; Cuciuc V; Zilberman L; Fugenfirov I; Meledin V; Shimoni S; Josfberg S; George J
PLoS One; 2021; 16(7):e0254104. PubMed ID: 34242301
[TBL] [Abstract][Full Text] [Related]
49. Diagnosing Transthyretin Cardiac Amyloidosis by Technetium Tc 99m Pyrophosphate: A Test in Evolution.
Poterucha TJ; Elias P; Bokhari S; Einstein AJ; DeLuca A; Kinkhabwala M; Johnson LL; Flaherty KR; Saith SE; Griffin JM; Perotte A; Maurer MS
JACC Cardiovasc Imaging; 2021 Jun; 14(6):1221-1231. PubMed ID: 33221204
[TBL] [Abstract][Full Text] [Related]
50. New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac Amyloidosis.
Perlini S; Mussinelli R; Salinaro F
Curr Heart Fail Rep; 2016 Dec; 13(6):267-272. PubMed ID: 27900617
[TBL] [Abstract][Full Text] [Related]
51. Multimodality imaging approach to cardiac amyloidosis: part 2.
Sennott J; Ananthasubramaniam K
Heart Fail Rev; 2022 Sep; 27(5):1515-1530. PubMed ID: 34694574
[TBL] [Abstract][Full Text] [Related]
52. Transthyretin Amyloid Cardiomyopathy-Current and Future Therapies.
Yadav JD; Othee H; Chan KA; Man DC; Belliveau PP; Towle J
Ann Pharmacother; 2021 Dec; 55(12):1502-1514. PubMed ID: 33685242
[TBL] [Abstract][Full Text] [Related]
53. Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms.
Gonzalez-Lopez E; Escobar-Lopez L; Obici L; Saturi G; Bezard M; Saith SE; AbouEzzeddine OF; Mussinelli R; Gagliardi C; Kharoubi M; Griffin JM; Dispenzieri A; Vilches S; Perlini S; Longhi S; Oghina S; Rivas A; Grogan M; Maurer MS; Damy T; Palladini G; Rapezzi C; Garcia-Pavia P
JACC CardioOncol; 2022 Nov; 4(4):442-454. PubMed ID: 36444226
[TBL] [Abstract][Full Text] [Related]
54. Cardiac [
Tingen HSA; Tubben A; Bijzet J; van den Berg MP; van der Meer P; Houwerzijl EJ; Muntinghe FLH; van der Zwaag PA; Glaudemans AWJM; Oerlemans MIFJ; Knackstedt C; Michels M; Hirsch A; Hazenberg BPC; Slart RHJA; Nienhuis HLA
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):681-690. PubMed ID: 37843599
[TBL] [Abstract][Full Text] [Related]
55. Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model.
Arvanitis M; Koch CM; Chan GG; Torres-Arancivia C; LaValley MP; Jacobson DR; Berk JL; Connors LH; Ruberg FL
JAMA Cardiol; 2017 Mar; 2(3):305-313. PubMed ID: 28196196
[TBL] [Abstract][Full Text] [Related]
56. Sex differences in transthyretin cardiac amyloidosis.
Aimo A; Panichella G; Garofalo M; Gasparini S; Arzilli C; Castiglione V; Vergaro G; Emdin M; Maffei S
Heart Fail Rev; 2024 Mar; 29(2):321-330. PubMed ID: 37566193
[TBL] [Abstract][Full Text] [Related]
57. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis.
Rapezzi C; Quarta CC; Guidalotti PL; Pettinato C; Fanti S; Leone O; Ferlini A; Longhi S; Lorenzini M; Reggiani LB; Gagliardi C; Gallo P; Villani C; Salvi F
JACC Cardiovasc Imaging; 2011 Jun; 4(6):659-70. PubMed ID: 21679902
[TBL] [Abstract][Full Text] [Related]
58. Multimodality assessments of wild-type transthyretin cardiac amyloidosis with no ventricular hypertrophy.
Iwaya T; Okada A; Tateishi E; Ohta Y; Morita Y; Ohta-Ogo K; Izumi C
ESC Heart Fail; 2023 Apr; 10(2):1412-1417. PubMed ID: 36335980
[TBL] [Abstract][Full Text] [Related]
59. Cardiac amyloidosis: Recent advances in the diagnosis and therapy.
Çavuşoğlu Y; Özpelit E; Çelik A; İkitimur B; Kayıkçıoğlu M; Tokgözoğlu L; Tüfekçioğlu O; Yılmaz MB
Turk Kardiyol Dern Ars; 2019 Jun; 47(Suppl 2):1-34. PubMed ID: 31364995
[TBL] [Abstract][Full Text] [Related]
60. Wild-Type Transthyretin Cardiac Amyloidosis: Novel Insights From Advanced Imaging.
Narotsky DL; Castano A; Weinsaft JW; Bokhari S; Maurer MS
Can J Cardiol; 2016 Sep; 32(9):1166.e1-1166.e10. PubMed ID: 27568874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
